Jody Charnow, Author at MPR

Jody Charnow

All articles by Jody Charnow

PARP-Inhibiting Drug May Improve mCRPC Outcomes

In a phase 3 trial of men with metastatic castration-resistant prostate cancer and altered DNA repair genes, olaparib-treated patients had significantly longer radiographic progression-free survival compared with enzalutamide or abiraterone recipients.